Faculty

Institution

Unit

Venue

Garrett Moraski

Research Scientist

Montana State University

Affiliations

College of Letters & Science

Department of Chemistry & Biochemistry

Garrett Moraski is currently serving as a College Of Letters & Science Research Scientist at Montana State University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Garrett Moraski

Montana State University

Research Scientist

You can click a keyword to filter the displayed items

pharmacology tuberculosis antimicrobial agents medicinal chemistry antibacterial agents biochemistry microbiology antimicrobial chemotherapy drug discovery antibiotics drug resistance infectious diseases enzyme inhibition clinical microbiology pharmaceutical chemistry chemical synthesis enzymes future medicinal chemistry chemical biology medicinal research biological chemistry protein science pharmacotherapy applied microbiology mycobacterium tuberculosis biochemical sciences pharmacological research pulmonary tuberculosis medical microbiology mycoprotein synthetic chemistry antituberculosis activity clinical chemistry redox biology microbial cell factory biomolecular structure protein chemistry antimicrobial compounds antibiotic resistance bacteriology carbonyl metabolism antitubercular agents improved pharmacokinetics dual inhibition buruli ulcer chemical sciences biological therapies herbal medicine herb-drug interactions anti-cancer agents drug development redox signaling drug targeting emerging infectious diseases redox chemistry biocatalysis catalytic process catalytic synthesis heme transport heme trafficking heme signaling infectious disease modelling host specificity histocompatibility enzyme specificity lipid synthesis dual read-out assay mycobactin-artemisinin conjugate potent activity oxazole benzyl esters structure-activity relationship new scaffold tubulin polymerization compound 13e nm activity terminal oxidases mycobacterial disease

Notable Scholarly Works

Notable Federal Grants

Collaborators

Gamf1.39'S Antibiotic Efficacy and Its Enhanced Antitubercular Activity in Combination With Clofazimine, Telacebec, Nd-011992, or Tbaj-876. Microbiology Spectrum (2023)

microbiologytuberculosismedicineantimicrobial agentspharmacological researchantimicrobial chemotherapyenhanced antitubercular activityantibioticspharmacologyfuture medicinal chemistryantibacterial agentsantimicrobial resistancepharmacotherapyantibiotic efficacy

Gamf1.39’S Antibiotic Efficacy and Its Enhanced Antitubercular Activity in Combination With Clofazimine, Telacebec, Nd-011992, or Tbaj-876. Microbiology Spectrum (2023)

microbiologytuberculosismedicineantimicrobial agentspharmacological researchantimicrobial compoundsantimicrobial chemotherapyenhanced antitubercular activityantibioticspharmacologyfuture medicinal chemistryantibacterial agentsantimicrobial resistancegamf1.39 ’pharmacotherapyantibiotic efficacy

Syntheses and Studies of Deuterated Imdiazo[1,2-a]Pyridine-3-Carboxamides With Potent Anti-Tuberculosis Activity and Improved Metabolic Properties. Bioorganic Chemistry (2022)

Rui LiuKate MarshallRui MaKim Lien Thi PhamGauri ShetyeZhihao LiuSanghyun ChoHyunyoung JeongScott G. FranzblauGarrett C. MoraskiMarvin J. Miller

microbiologytuberculosischemical synthesisbioorganic chemistrysynthetic chemistryorganic synthesispharmacologymetabolic propertiessynthetic biologymolecular biology

Syntheses and Studies of Deuterated Imdiazo[1,2-a]Pyridine-3-Carboxamides With Potent Anti-Tuberculosis Activity and Improved Metabolic Properties.. (2022)

organic process researchheterocycle chemistryorganic chemistrybiomolecular engineeringchemical synthesispotent anti-tuberculosis activitymedicinal chemistrysynthetic chemistryorganic synthesispharmacologymetabolic propertiesenzyme inhibition

Dual Inhibition of the Terminal Oxidases Eradicates Antibiotic-Tolerant Mycobacterium Tuberculosis. EMBO MOLECULAR MEDICINE (2021)

microbiologytuberculosispathogenic bacteriaantibiotic resistanceantimicrobial agentsantimicrobial chemotherapydrug resistancedual inhibitionantibioticsbiochemistrypharmacologyantibacterial agentsantimicrobial resistanceapplied microbiology

Hydride-Induced Meisenheimer Complex Formation Reflects Activity of Nitro Aromatic Anti-Tuberculosis Compounds. RSC Medicinal Chemistry (2021)

Rui LiuLowell MarkleyPatricia A. MillerScott FranzblauGauri ShetyeRui MaKarin SavkováKatarína MikušováBei Shi LeeKevin PetheGarrett C. MoraskiMarvin J. Miller

tuberculosisinfectious diseasesmedicinal chemistrypharmacologymolecular biologydrug discovery

Structure Guided Generation of Thieno[3,2- D ]Pyrimidin-4-Amine Mycobacterium Tuberculosis Bd Oxidase Inhibitors. RSC Medicinal Chemistry (2021)

pharmaceutical chemistrybiomolecular engineeringchemical synthesischemical biologybiological macromoleculesrational drug designcheminformaticsbioorganic chemistrycombinatorial chemistrybiomolecular structurebiochemistryfuture medicinal chemistrymolecular biologyenzyme inhibitiondrug discoverydiversity oriented synthesis

Syntheses and Structure–Activity Relationships of N-Phenethyl-Quinazolin-4-Yl-Amines as Potent Inhibitors of Cytochrome Bd Oxidase in Mycobacterium Tuberculosis. Applied Sciences (2021)

tuberculosisstructure–activity relationshipsenzymespharmaceutical chemistrymycobacterium tuberculosischemical biologycytochrome bd oxidasepulmonary tuberculosisbiochemistrypharmacologyantibacterial agentsantimicrobial agentsenzyme inhibitiondrug discovery

Dual Inhibition of the Terminal Oxidases Eradicates Antibiotic‐Tolerant Mycobacterium Tuberculosis. EMBO Molecular Medicine (2020)

Bei Shi LeeKiel HardsCurtis A EngelhartErik J HasenoehrlNitin P KaliaJared S MackenzieEkaterina SviriaevaShi Min Sherilyn ChongMalathy Sony S ManimekalaiVanessa H KohJohn ChanJiayong XuSylvie AlonsoMarvin J MillerAdrie J C SteynGerhard GrüberDirk SchnappingerMichael BerneyGregory M CookGarrett C MoraskiKevin Pethe

antibiotic resistancetuberculosismedicineenzymesveterinary medicineinfection controlinfectious diseasesdrug resistancedual inhibitionterminal oxidasesclinical microbiologypharmacologyenzyme inhibitionpharmacotherapymolecular medicine

Intracellular and in Vivo Evaluation of Imidazo [2,1-B]Thiazole-5-Carboxamide Antituberculosis Compounds. PLOS ONE (2020)

bioactive compoundsin vitro toxicologydrug resistanceantimicrobial chemotherapyantiparasitic agentvivo evaluationbiochemistrypharmacologyantibacterial agentstherapeutic targetsmolecular pharmacologyenzyme inhibitiondrug discovery

1
2
3
4
5
10 / page

Garrett Moraski

Research Scientist

Montana State University

Affiliations

College of Letters & Science

Department of Chemistry & Biochemistry

Garrett Moraski is currently serving as a College Of Letters & Science Research Scientist at Montana State University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Garrett Moraski

Montana State University

Research Scientist

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Gamf1.39'S Antibiotic Efficacy and Its Enhanced Antitubercular Activity in Combination With Clofazimine, Telacebec, Nd-011992, or Tbaj-876. Microbiology Spectrum (2023)

Gamf1.39’S Antibiotic Efficacy and Its Enhanced Antitubercular Activity in Combination With Clofazimine, Telacebec, Nd-011992, or Tbaj-876. Microbiology Spectrum (2023)

Syntheses and Studies of Deuterated Imdiazo[1,2-a]Pyridine-3-Carboxamides With Potent Anti-Tuberculosis Activity and Improved Metabolic Properties. Bioorganic Chemistry (2022)

Rui LiuKate MarshallRui MaKim Lien Thi PhamGauri ShetyeZhihao LiuSanghyun ChoHyunyoung JeongScott G. FranzblauGarrett C. MoraskiMarvin J. Miller

microbiologytuberculosischemical synthesisbioorganic chemistrysynthetic chemistryorganic synthesispharmacologymetabolic propertiessynthetic biologymolecular biology

Syntheses and Studies of Deuterated Imdiazo[1,2-a]Pyridine-3-Carboxamides With Potent Anti-Tuberculosis Activity and Improved Metabolic Properties.. (2022)

Dual Inhibition of the Terminal Oxidases Eradicates Antibiotic-Tolerant Mycobacterium Tuberculosis. EMBO MOLECULAR MEDICINE (2021)

Hydride-Induced Meisenheimer Complex Formation Reflects Activity of Nitro Aromatic Anti-Tuberculosis Compounds. RSC Medicinal Chemistry (2021)

Rui LiuLowell MarkleyPatricia A. MillerScott FranzblauGauri ShetyeRui MaKarin SavkováKatarína MikušováBei Shi LeeKevin PetheGarrett C. MoraskiMarvin J. Miller

tuberculosisinfectious diseasesmedicinal chemistrypharmacologymolecular biologydrug discovery

Structure Guided Generation of Thieno[3,2- D ]Pyrimidin-4-Amine Mycobacterium Tuberculosis Bd Oxidase Inhibitors. RSC Medicinal Chemistry (2021)

Syntheses and Structure–Activity Relationships of N-Phenethyl-Quinazolin-4-Yl-Amines as Potent Inhibitors of Cytochrome Bd Oxidase in Mycobacterium Tuberculosis. Applied Sciences (2021)

Dual Inhibition of the Terminal Oxidases Eradicates Antibiotic‐Tolerant Mycobacterium Tuberculosis. EMBO Molecular Medicine (2020)

Intracellular and in Vivo Evaluation of Imidazo [2,1-B]Thiazole-5-Carboxamide Antituberculosis Compounds. PLOS ONE (2020)

1
2
3
4
5
10 / page

Similar Faculty Members

Robert Kerns

Institution

University of Iowa

pharmaceutical research

pharmacology

Dr. James Leahy

Institution

University of South Florida

biomolecular engineering

drug development

Dennis Wright

Institution

University of Connecticut

future medicinal chemistry

complex natural products

Mayland Chang

Institution

University of Notre Dame

pathology

cancer cell

Timothy Wencewicz

Institution

Washington University in St. Louis

biological chemistry

biomolecular engineering

John D. Buynak

Institution

Southern Methodist University

organic chemistry

medicinal chemistry

Daniel Lim

Institution

University of South Florida

pathogenic bacteria

infectious diseases

Peter J. Tonge

Institution

Stony Brook University

biological data

biomedical informatics

Charles E. McKenna

Institution

University of Southern California

future medicinal chemistry

medicinal chemistry

Paul R. Carlier

Institution

University of Illinois Chicago

infectious diseases (medical specialty)

malaria

Similar Faculty Members

Robert Kerns

Institution

University of Iowa

pharmaceutical research

pharmacology

Dr. James Leahy

Institution

University of South Florida

biomolecular engineering

drug development

Dennis Wright

Institution

University of Connecticut

future medicinal chemistry

complex natural products

Mayland Chang

Institution

University of Notre Dame

pathology

cancer cell

Timothy Wencewicz

Institution

Washington University in St. Louis

biological chemistry

biomolecular engineering

John D. Buynak

Institution

Southern Methodist University

organic chemistry

medicinal chemistry

Daniel Lim

Institution

University of South Florida

pathogenic bacteria

infectious diseases

Peter J. Tonge

Institution

Stony Brook University

biological data

biomedical informatics

Charles E. McKenna

Institution

University of Southern California

future medicinal chemistry

medicinal chemistry

Paul R. Carlier

Institution

University of Illinois Chicago

infectious diseases (medical specialty)

malaria